HMG-CoA reductase inhibitors in the prevention of restenosis following coronary angioplasty

摘要

Treatment of coronary patients scheduled to undergo percutaneous transluminal coronary angioplasty (PTCA) for several days before the procedure and a prolonged period afterwards with doses of a HMG-CoA reductase inhibitor to aggressively lower total and LDL cholesterol prevents intimal hyperplasia at the angioplasty site reducing clinical and angiographic evidence of restenosis.